Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07491367 · ClinicalTrials.gov registry record · Phase 4
Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems
A Phase 4 study, sponsored by University of California, San Francisco.
- Not yet
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT07491367: Clinical Trial Phase 4 study, sponsored by University of California, San Francisco.
NCT07491367 is a Phase 4 study that has not yet begun recruiting, run by University of California, San Francisco. The registered enrollment target is 20 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07491367, a Phase 4 study, has not yet begun recruiting, sponsored by University of California, San Francisco.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The investigators would like to study the differences in the quality of Platelet Rich Plasma (PRP) between two different machines in those with knee osteoarthritis. Knee osteoarthritis means your cartilage has been worn down, and it affects your knee joint. Both machines, the APEX Biologix XCELL PRP System and the Emcyte PurePRP Supraphysiologic Concentrating System, are FDA approved, commercially available, and makes PRP. The investigators will check if the platelets in the PRP have different amounts or work differently. The investigators will also assess participants symptoms after the injection and compare the two different preparation systems.
Primary Outcome
Compare cellular composition and quantifying PRP products between EmCyte PurePRP versus APEX Biologix XCELL PRP manufacturing systems using a Horiba Cell counter.
Interventions
- BIOLOGICAL Platelet Rich Plasma
- DEVICE Emcyte PurePRP Supraphysiologic Concentrating System
- DEVICE APEX Biologix XCELL PRP System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2028-09 |
| Phase | Phase 4 |
What is known before NCT07491367 opens enrollment
NCT07491367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Platelet Rich Plasma is the first listed.
NCT07491367 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07491367 about?
NCT07491367 is a clinical study titled "Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems". The investigators would like to study the differences in the quality of Platelet Rich Plasma (PRP) between two different machines in those with knee osteoarthritis. Knee osteoarthritis means your cartilage has been worn down, and it affects your knee joint. Both machines, the APEX Biologix XCELL PRP...
What is the current status of trial NCT07491367?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2026-07-01. Estimated completion is 2028-09.
What interventions are being tested in trial NCT07491367?
The interventions under investigation include: Platelet Rich Plasma (BIOLOGICAL), Emcyte PurePRP Supraphysiologic Concentrating System (DEVICE), APEX Biologix XCELL PRP System (DEVICE).
Who is sponsoring clinical trial NCT07491367?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07491367's enrollment target sits among peer trials
20 1753rd of 2000 higher than 167 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI